Jan 29 |
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
|
Dec 20 |
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
|
Dec 18 |
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
|
Dec 4 |
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
|
Nov 30 |
Recap: Can Fite Biofarma Q3 Earnings
|
Nov 30 |
Can-Fite Biopharma GAAP EPS of $0.00 beats by $0.43, revenue of $0.59M beats by $0.39M
|
Nov 30 |
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
|
Nov 22 |
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
|
Nov 21 |
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
|
Nov 21 |
Can-Fite climbs on mid-stage data for liver cancer therapy
|